Additional information Active substance GHRH Peptide Storage conditions Store in a refrigerator at 2В°C to 8В°C (36В°F to 46В°F) Side effects Injection site reactions (redness, itching, pain), muscle aches, swelling, and potential increase in blood sugar levels Effects Increases natural production of growth hormone Dosage (sports) Not applicable as it is not typically used for sports enhancement Dosage (medical) 2 mg injected subcutaneously once daily Half-life Approximately 38 minutes Main action Growth hormone-releasing hormone (GHRH) analog Substance class Peptide hormone Formula C221H366N72O67S Chemical name (trans-3-Hexenoyl)lysyl-threonyl-threonyl-threonyl-lysyl-threonyl-lysyl-threonyl-lysyl-threonyl-lysyl-threonyl-lysyl-threonyl Trade name Egrifta Blood pressure Typically no significant impact on blood pressure WAREHOUSE International Warehouse 3 Also known as TH9507 Lab Test Monitoring of IGF-1 levels may be used to assess efficacy Aromatization No Hepatotoxicity No HBR No Water Retention No Acne No Use in sports Not commonly used due to its specific medical application for reducing excess abdominal fat in HIV-infected patients with lipodystrophy Manufacturer Beligas
